Literature DB >> 9472425

Acute fulminant SSPE: clinical and EEG features.

Z Gökçil1, Z Odabaşi, A Aksu, O Vural, M Yardim.   

Abstract

We report an autopsy-proven case of SSPE in which the course was rapidly progressive, leading to death in 2 months. The patient was admitted for investigation of visual symptoms. His examination revealed complete right homonymous hemianopia and myoclonic jerks in the right half of the body. EEG showed high voltage periodic slow-wave discharges that were often associated with jerks. Measles antibody was positive in serum and CSF. MRI showed hyperintensity in the white matter of the occipital poles. The patient became completely blind and had jerks in all four limbs. His condition continued to deteriorate and within 3 weeks he reached a state of deep coma. The myoclonic jerks became less marked and gradually completely ceased. The EEG showed diffuse slow activity without periodic complexes. The patient died approximately 2 months from onset of disease. Brain autopsy revealed severe neuronal loss with abundant inclusion bodies in the remaining neuronal and oligodendroglial nuclei, which was compatible with SSPE.

Entities:  

Mesh:

Year:  1998        PMID: 9472425     DOI: 10.1177/155005949802900112

Source DB:  PubMed          Journal:  Clin Electroencephalogr        ISSN: 0009-9155


  3 in total

Review 1.  Subacute sclerosing panencephalitis.

Authors:  R K Garg
Journal:  Postgrad Med J       Date:  2002-02       Impact factor: 2.401

2.  Fulminant adult-onset subacute sclerosing panencephalitis: a case report.

Authors:  Anthony Faivre; Jean-Baptiste Souraud; Aileen McGonigal; Philippe Alla; Jacques Grapperon; Jacques Valance
Journal:  BMJ Case Rep       Date:  2009-03-02

3.  A rare presentation of subacute sclerosing panencephalitis with acute fulminant course and atypical radiological features.

Authors:  Rajendra Singh Jain; Raghavendra Bakki Sannegowda; Trilochan Srivastava; Rahul Jain; Tarun Mathur; Pankaj Gandhi
Journal:  Ann Indian Acad Neurol       Date:  2013-10       Impact factor: 1.383

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.